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Background: Primary hyperparathyroidism (PHPT) and metabolic syndrome (MS) have been independently related
to cardiovascular morbidities, however this association is still controversial. Mexican population has a high prevalence of
metabolic syndrome, however its frequency seems to be even higher than expected in patients with PHPT.
Methods: We retrospectively reviewed the charts of patients that underwent parathyroidectomy for PHPT in a referral
center and used the criteria from the National Cholesterol Educational Program (NCEP)/Adult Treatment Panel III (ATP III)
to define MS before surgery. We compared the characteristics between the patients with and without MS.
Results: 60 patients were analyzed, 77% were female and 72% had a single parathyroid adenoma. MS was present in
59% of the patients, this group was significantly older (57 vs. 48 years, p = 0.01) and they had lower iPTH (115 vs. 161
ng/ml, p = 0.017). Other parameters did not show differences.
Conclusions: MS is frequent in our population diagnosed with primary hyperparathyroidism, adverse cardiovascular
parameters are common and significant differences in calcium metabolism compared to the non-MS group are present.
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Primary hyperparathyroidism (PHPT) is a common endo-
crine disease, particularly in postmenopausal women. It is
the main cause of hypercalcemia in outpatient settings and
its prevalence is estimated to be 1 to 4 per 1000 people in
the general population and 21 per 1000 in postmenopausal
women [1]. The estimated incidence is 15.7/100.000 people
/year in the USA [2].
PHPT is also associated with an increased risk of car-
diovascular mortality [3-5]. Recent evidence shows that
it is also associated with metabolic disorders and other
components of metabolic syndrome (MS) such as hyper-
tension (HTN), dyslipidemia, glucose intolerance, obes-
ity, insulin resistance and reduced insulin secretion
[6-8]. The ethiopathogenic mechanisms of MS are not* Correspondence: vmendozazu@yahoo.com
1Endocrinology Departament Hospital de Especialidades Centro Médico
Nacional Siglo XXI, Instituto Mexicano del Seguro Social (IMSS), Cuauhtemoc
N° 330, Colonia Doctores, México City, DF, Mexico
Full list of author information is available at the end of the article
© 2015 Mendoza-Zubieta et al.; licensee BioM
Creative Commons Attribution License (http:/
distribution, and reproduction in any medium
Domain Dedication waiver (http://creativecom
article, unless otherwise stated.completely understood and the association with calcium
metabolism is being studied, since calcium is essential
for many metabolic processes. Additionally, changes in
vitamin D levels and other hormones in obese popula-
tions and patients with PHPT could be involved in the
pathogenesis of cardiovascular and metabolic comorbidi-
ties. The association between these entities is complex and
may be a source of additional morbidity and mortality.
The prevalence of MS, obesity and insulin resistance
have increased continuously all around the world. Each
one of them have been well documented as causes of
increased cardiovascular morbidity and mortality [9-11].
However, the prevalence of MS varies according to def-
inition criteria, age, sex and population studied. Between
1999–2010 the National Health and Nutrition Examin-
ation Survey (NAHNES) in USA reported an accumu-
lated prevalence of 25.5% in adults older than 20 years
of age; this prevalence decreased to 22.9% in 2010 [12].
In Europe the Diabetes Epidemiology: Collaborative
Analysis of Diagnostic Criteria in Europe (DECODE)ed Central. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
Mendoza-Zubieta et al. BMC Endocrine Disorders  (2015) 15:16 Page 2 of 7reported a prevalence of MS of 41% for male population
and 38% for female population according to International
Diabetes Federation (IDF) criteria [13]. In Mexico, the
prevalence in adults older than 20 years of age is 41.6% ac-
cording to the criteria proposed by the American Heart
Association/National Heart Blood and Lung Institute
(AHA/NHLBI) and 42% using the (NCEP:ATPIII) criteria
[14]. Some polymorphisms associated altered lipid metabol-
ism pathways are frequent in Mexico, which may be associ-
ated with the higher prevalence of MS in this mestizo
population [15,16], however, other components of the MS
are also frequent in these population. These data suggests
that MS is twice as prevalent in our population compared
to other countries, which also may have an influence on the
calcium and vitamin D metabolism in both physiological
and pathological states. The ethiopathogenic relationship
between PHPT and MS is currently being investigated, it‘s
unclear if the association of these two entities will affect
mortality in the long term. Since Hispanic populations
seem to be especially prone to high risk profiles for cardio-
vascular disease, specific analysis of these groups may help
determine which patients require special diagnostic or
treatment algorithms.
The purpose of this study was to evaluate the preva-
lence of MS in patients with PHPT and to compare the
clinical and biochemical characteristics of patients with
and without MS.
Methods
This cross-sectional study included patients from the
Bone and Calcium Metabolism Clinic of the Hospital de
Especialidades Centro Medico Nacional Siglo XXI diag-
nosed with PHPT during a 3 year-period between 2006
and 2009. A general evaluation including anthropometry
was performed in all patients before surgery. We evalu-
ated the signs and symptoms related to hypercalcemia
(repeated nephrolithiasis, gastritis, polyuria, muscle
weakness, osteosteoporosis or psychiatric disorders),
personal history of bone fractures and we assessed bio-
chemically for hypercalcemia, high blood level of intact
parathyroid hormone (iPTH) and hypophosphatemia.
Nephrolithiasis diagnosis was assessed through kidney
ultrasonography only in patients with related symp-
toms. We also performed a bone densitometry through
DEXA (dual-energy X-ray absorptiometry) to evaluate
osteopenia or osteoporosis. We performed calcium:cre-
atinine clearance ratio only in asymptomatic patients
with a family history of hypercalcemia in order to dif-
ferentiate between PHPT and familial hypocalciuric hy-
percalcemia (data not shown). Patients were subjected
to localization studies such as neck ultrasonography
and Tc99-sestamibi scintigraphy. Only the patients
with confirmed PHPT (symptomatic or asymptomatic),
which had an indication for surgery (serum calcium >1.0 mg/dl above upper limit of normal range, BMD T
score ≤ −2.5 at any site or fragility fracture, calculated
glomerular filtration rate below 60 ml/min and age ≤
50 years, according the Third International Workshop
[17]), were included in the final analysis. After surgery,
histopathology report was also reviewed. Subjects with in-
complete clinical, pathology or biochemical evaluation were
eliminated. Sixty patients fulfilled these criteria and were in-
cluded for analysis. Information about demographic charac-
teristics, previous diseases as hypertension, impairment of
glucose metabolism (defined as impaired glucose tolerance
in an oral glucose tolerance test or impaired fasting glu-
cose) T2DM, dyslipidemia or obesity, diet and exercise
habits were obtained from medical records.
The study was performed according to Declaration of
Helsinki II and completed all the requirements of the
local ethics committee (Comité Local de Investigación y
Ética en Investigación en Salud). The protocol and the
aim of the study were fully explained to the subjects,
who gave their written consent.
Diagnostic criteria of the metabolic syndrome
Metabolic syndrome was defined according to the NCEP:
ATPIII criteria as the presence of three or more of follow-
ing components: waist circumference (WC) ≥102 cm in
men and 88 cm in women, triglycerides > 150 mg/dl,
c-HDL < 40 mg/dl in men and <50 mg/dl in women or a
previously treated dyslipidemia, Systolic Blood Pressure of
130 mmHg or Diastolic Blood Pressure of 85 mm Hg or
physician’s diagnosis of hypertension or patients receiv-
ing treatment with antihypertensive drugs and fasting
glucose >100 mg/dl or physician’s diagnosis of diabetes [18].
Anthropometric measurements
At the time of evaluation we registered weight (kilo-
grams) and height (meters), as well as waist circumfer-
ence [WC] (centimeters). A single investigator, using the
same calibrated scale with an integrated stadiometer,
performed all the anthropometric measurements. WC
was determined at the middle point between the inferior
rim of the last costal arch and the superior rim of the
anterosuperior iliac spine. Central obesity was defined
using WC as previously mentioned. Body mass index
(BMI) was calculated as the weight divided by height to
the square. Those patients with BMI between 25–
29.9 kg/m2 were considered overweight and the ones
with a BMI ≥30 kg/m2 were considered obese according
to World Health Organization (WHO) criteria. Blood
pressure was determined in the left arm, after 10 minutes
in a resting position, during a fasting state, without
coffee or tobacco ingestion in the last week. The sphyg-
momanometer was calibrated and values were averaged
after 2 different measurements with a 5-minute differ-
ence between them.
Table 1 Baseline characteristics of patients with PHPT
Parameter n = 60
Age (years), mean ± SD 53.5 ± 13.9
Female (%) 77
Weight (kg), median (IR) 68.2 (61.1-81.4)
Height (m), mean ± SD 1.57 ± 0.09
BMI (kg/m2), mean ± SD 29.08 ± 4.9
Waist (cm), median (IR) 91.5 (82.5-106.5)
Female 90.5 (83.5-105.5)
Male 97 (82–109)
Glucose (mg/dl), median (IR) 103 (87–115)
Calcium (mg/dl), mean ± SD 11.1 ± 1.09
Phosphorus (mg/dl), mean ± SD 3.08 ± 0.68
iPTH (ng/ml), median (RI) 127.5 (84.5-185)
Triglycerides (mg/dl), median (IR) 189.5 (130–269)
c-HDL (mg/dl), mean ± SD 47.3 ± 11.8
Female 48.7 ± 12.27













Abbreviations: BMI = body mass index, iPTH = intact parathyroid hormone,
SD = standard deviation, IR = interquartile range.
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For biochemical determinations all patients fulfilled a
fasting state of 12 hours. Laboratory results were ob-
tained with a 6 mL sample in BD Vacutainer (BD Frank-
lin Lakes, New Jersey USA), centrifuged at 3150 x g for
15 minutes and serum was then analyzed with a kit for
glucose, cholesterol, c-HDL and triglycerides (COBAS
2010 Roche Diagnostics, Indianapolis USA) using photoco-
lorimetry with spectrophotometer Roche Modular P800
(2010 Roche Diagnostics, Indianapolis USA). c-HDL sam-
ples were treated with enzymes modified with polyethilene-
glycol and dextrane sulphate, analyzed with the same
photocolorimetric technique. We used a specific chemiolu-
miniscent assay to measure iPTH (DiaSorin Inc, Stillwater,
Minnesota) with a sensitivity of 1 pg/ml and inter- and
intra-assay coefficient of variation (CV) of 5.3% and 3.5%,
respectively. Serum calcium (Ca) and phosphate (P) were
tested using automated methods based on colorimetric and
enzymatic assays (COBAS, Roche).
Statistical analysis
Results are expressed according to sample distribution
with means and standard deviations (SD) or medians
and interquartile ranges (IQR). Kolmogorov-Smirnov
test was used to determine normality. To establish asso-
ciations between quantitative variables, Student’s t test
or Mann–Whitney U test were used. Qualitative vari-
ables were associated with χ2 or Fisher tests. Correla-
tions between quantitative variables were tested with
Pearson or Spearman test. A p < 0.05 was considered to
be significant. Data were analyzed with SPSS v.16.
Results
Anthropometrical and clinical characteristics
Sixty patients with an average age of 53 years, completed
clinical and biochemical assessment: 46 female and 14
male with a proportion of 3:1. According to our data,
65% of patients have a family history for T2DM and
48.3% for hypertension (data not shown). We found that
60% of patients (n = 36) had impaired glucose metabol-
ism, 30% of patients had T2DM (n = 18), 68% (n = 41)
had hypertriglyceridemia, 62% (n = 37) had central obes-
ity, 40% (n = 24) had hypertension and 52% (n = 31) had
low c-HDL concentration. In total, 60% (n = 36) of the
patients with PHPT fulfilled MS diagnostic criteria ac-
cording to the NCEP:ATPIII definition. Baseline charac-
teristics of population are referred in Table 1.
When we compared patients with PHPT and MS (n =
36) and without MS (n = 24), we found that 89% had
hypertriglyceridemia, 78% had alterations of glucose me-
tabolism, 44% had T2DM, 83% had central obesity (ac-
cording to sex), 58% had hypertension and 64% had low
c-HDL concentration. In the group of patients that did
not fulfill the MS criteria 29% (n = 7) had central obesity,13% (n = 3) had HTN, 38% (n = 9) had hypertriglyc-
eridemia, 33% (n = 8) had low c-HDL concentration,
33% (n = 8) had alterations on glucose metabolism and
8% (n = 2) had T2DM. It is noteworthy that not one of
the patients in this study had completely normal meta-
bolic parameters. Table 2 depicts other clinical and bio-
chemical differences between groups. Considering that
the age between groups was statistically different, we
performed a stratified analysis dividing patients by age
and sex. Most clinical and laboratory parameters were
similar between these groups except for hypertension.
Hypertensive patients were significantly older than the
normotensive ones in both genders (66 + 20.2 years of
age vs. 43 + 15.9, p = 0.037 for males and 60.7 + 9.8 vs.
49.7 + 10.7, p = 0.001 for females).
Table 2 Baseline clinical and biochemical characteristics of patients with PHPT with and without MS
With MS Without MS p
Age (y), mean ± SD 57.2 ± 12.6 48 ± 14.2 0.014a
Female, n (%) 27 (75) 19 (79) 0.78
Weight (kg), median (IR) 73 (63–85) 63.5 (54–71) 0.010b
Height (m), mean ± SD 1.57 ± 0.09 1.56 ± 0.09 0.65
BMI (kg/m2), mean ± SD 30.3 ± 4.58 27.1 ± 5.02 0.017a
Glucose (mg/dl), median (IR) 107 (96.7-126.5) 90 (84.5-102.7) 0.006b
Calcium (mg/dl), mean ± SD 10.8 ± 0.93 11.43 ± 1.25 0.07a
Phosphorus (mg/dl), mean ± SD 3.2 ± 0.60 2.9 ± 0.77 0.114
iPTH (ng/ml), median (IR) 115 (73.6-154.2) 161.5 (100.9-231.5) 0.017b
Triglycerides (mg/dl), median (IR) 231.5 (168.7-289.5) 133 (113.7-178.2) <0.001b
c-HDL (mg/dl), mean ± SD
Female
Male 46.19 ± 12.6 52.42 ± 11.08 0.090
41.78 ± 11.14 44.6 ± 4.72 0.604
Central obesity, n (%) 30(83) 7(29) <0.001c
Hypertension, n(%) 21(58) 3(12.5) <0.001c
Hypertriglyceridemia, n(%) 32(89) 9(38) <0.001c
Low c-HDL concentration (%) 23(64) 8(33) 0.019c
Impairment of glucose metabolism, n(%) 28(78) 8(33) 0.001c
T2DM, n(%) 16(44) 2(8) 0.002c
Abbreviations: BMI = body mass index, T2DM = type 2 diabetes mellitus, IR = interquartile range, iPTH = intact parathyroid hormone. aStudent t test, bMann–Whitney
U test, cFisher’s exact test.
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weight and 33% were obese (according to BMI). In pa-
tients with MS the prevalence of obesity increased to
39% while overweight was present in 47%. In patients
without MS the prevalence of excess weight and obesity
was 21% and 25%, respectively; also, 87% of them had at
least one component of MS.
We found that iPTH levels were higher in patients
without MS (Table 2). Despite levels were not significant
between groups, we found that phosphorus levels were
negatively correlated with iPTH (ρ = −0.416, p = 0.001)
and that calcium levels were higher in patients without
MS. We did not find any correlation between iPTH, cal-
cium and other metabolic parameters (data not shown).
Discussion
Our study shows that Mexican patients with PHPT have
the highest prevalence of MS reported so far, reaching a
staggering 60% of the cases. However, we should note
that MS prevalence varies widely depending on diagnos-
tic criteria used and the population studied. Nonetheless,
other authors using the same criteria (NCEP:ATPIII cri-
teria) reported lower prevalences; deLuis et al. reported
a prevalence of MS of 32.3% in 62 patients with PHPT
from Spain [19], Procopio et al. [20] found a prevalence
of 47.6% in patients classified as low-risk asymptomatic,8.7% in symptomatic patients and 8.3% in high-risk
asymptomatic patients and Luigi et al. [21] reported a
prevalence of 38% in 30 patients from University of
Rome “Sapienza”, Italy. In fact, according to our results,
the presence of MS could be involved in the increased
cardiovascular risk observed in patients with PHPT,
which contrasts with Tassone et al. who reported that
MS prevalence was similar between patients with PHPT
and the general Italian population (Progetto Cuore
Study) [22]. Unfortunately we don’t have enough infor-
mation comparing symptomatic or asymptomatic pa-
tients to compare with this group. At this point, we
should consider that Mexico has one of the highest
prevalences of obesity and hypoalphalipoproteinemia in
the world (76.3% according to national health survey
“ENSANUT 2006”), which may bias the whole sample
and artificially increase the overall prevalence of MS.
However the prevalence of MS is even higher in the pa-
tients with PHPT than in the general population of
Mexico (36% according to ENSANUT 2006) [14]. More
studies are required to assess if the presence of MS is in-
volved in the higher frequency of cardiovascular risk fac-
tors associated with PHPT.
MS components are related to insulin resistance [10].
In our country, recent national health survey “ENSA-
NUT 2012” reported that the prevalence of overweight
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the 70% in our present findings. It seems that fatty acids
released from adipose tissue in obese patients causes in-
sulin resistance through disruption in insulin signaling
cascade [24], increased inflammation, oxidative stress,
coagulation abnormalities, endothelial damage, myocar-
dial dysfunction and accelerated atherosclerosis [10,11].
We found that central obesity is one of the most fre-
quent components of MS in this group (83% in MS
group vs. 29% in the non-MS group, p < 0.001), just sec-
ond to hypertriglyceridemia. The high prevalence of cen-
tral obesity in these patients could be explored as the
major cause of cardiovascular risk.
There are certain molecular associations between adi-
pose tissue and PHTP. Some in vitro experiments
showed that the increased levels of PTH rises intracellu-
lar calcium inside the adipocyte, promoting an increase
in its activity for as much as 50-100%, and an increase in
the expression of fatty acid synthetase, increase in the
activity of glycerol-3-phosphate dehydrogenase and in-
hibition of basal lipolysis [25]. These changes could be
associated to the increased lipogenesis and an increase
in adipocyte volume and could contribute to hypertri-
glyceridemia, which was higher than reported for general
population (31.4%) [14]. On other hand, it has also been
demonstrated that PTH stimulates the adipose tissue
differentiation and increases insulin resistance in these
cells [26] in correlation to the adipose tissue mass. Fi-
nally, some studies suggest that increased fat mass in-
duced by the increased concentrations of PTH acts as a
leptin mediator [27]. Nonetheless de-Luis et al. [19]
found that serum levels of leptin and adiponectin are
not related to iPTH, vitamin D or calcium levels in pa-
tients with PHPT. Further data is required to clarify the
inflammation component of PHPT in MS.
Other studies correlate the increased mass of adipose
tissue with the decrease in the 25-hidroxyvitamin D con-
centration as well and a secondary form of hyperpara-
thyroidism [28]. This deficiency in vitamin D seems to
be associated to abnormalities in the carbohydrate me-
tabolism but pharmacological approaches haven’t shown
favorable results [29]. Norenstedt et al. [30] studied 150
patients with PHPT after parathyroidectomy randomized
in two groups, one with oral calcium carbonate and the
other with calcium carbonate plus cholecalciferol. These
authors found no improvement in metabolic parameters
after one year of supplementation, despite the decrease
in PTH levels. In the period where these patients were
studied, vitamin D was not considered to be part of the
diagnostic algorithm of PHPT and therefore was not
available in our hospital. We consider that the low
serum calcium reported in most of these patients, and
even lower concentrations found in MS patients may
have multiple causes. For once, it may be related tosevere vitamin D deficiency, which is very frequent in
the Mexican population (24% vs. 1% in other popula-
tions) [31] and has been reported to be even lower in
obese patients [32]. The lower vitamin D concentrations
usually seen in Mexican patients may have an impact in
the calcium metabolism reported in our patients. Also,
most of the patients were classified as having a relatively
mild hyperparathyroidism, which is usually accompanied
by lower serum calcium and PTH levels, unlike other
reports were hyperparathyroidism was detected in
more advanced stages. Other authors showed that
obese patients with PHPT usually have higher PTHi
levels than the ones in our report; however, all pa-
tients fulfilled diagnostic criteria for PHPT and had
other indications for surgery, such as recurrent lithia-
sis or severe osteoporosis. Also, pathologic and ima-
genologic studies confirmed diagnosis. Clinical data
associated with hyperparathyroidism may be an im-
portant consideration when a patient has a mildly al-
tered laboratory results but damage to target organs
such as bone or kidney are present.
Hyperparathyroidism (in any of its clinical presenta-
tions) is associated with altered carbohydrate metabol-
ism and a disturbed insulin secretion or impaired
cellular sensitivity [33,34]. In fact, Kumar et al. found
that insulin sensitivity was lower in PHTP patients in
comparison with a control group (60% vs. 113.7%) [35].
Procopio et al. found that almost 40% of patients with
hyperparathyroidism have glucose intolerance in com-
parison with 25% found in healthy controls [33,34]. On
the other hand, the prevalence of PHPT in patients with
T2DM is 15%, (3 to 5 times higher than in patients with-
out diabetes) [14]. According to data from ENSANUT
2012 the prevalence of T2DM in general population was
8.9% for patients between 40 to 49 years old and 19.2%
for patients between 50 to 59 years old [36]. In our
study, the prevalence of T2DM was 44%, twice than that
reported for general population in any age group.
Regarding hypertension, we observed a prevalence of
40% in PHPT patients that is higher than in general popu-
lation: 32.4% for male and 31.1% for female, [37,38]. A pre-
vious study has suggested that calcium levels are implicated
in the pathogenesis of hypertension [39]. It seems that the
increase in PTH levels promotes endothelial calcium influx
and vasoconstriction. At this point, Petramala et al. found a
positive correlation between iPTH levels and blood pres-
sure [21]. However, in our study calcium and PTH levels
were lower in patients with MS in comparison with patients
without MS. This was also observed by Procopio et al. [20]
and suggests that other metabolic a, such as vitamin D defi-
ciency, could be involved.
Age and sex may be factors associated with the devel-
opment of metabolic syndrome. In our study, the group
with MS was statistically older than the group without
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Pairing patients by age or following them for several
years, may reveal differences in the development of MS
between patients treated surgically and the ones that
haven’t, however, this study may not be ethical in pa-
tients with overt or severe PHPT. Long term follow up
studies have not been conclusive in terms of determining
the usefulness of treating PHPT in order to improve car-
diovascular risk profiles, since most of them have been
followed for periods of around 1 year after surgery,
which is not enough to correct some biochemical abnor-
malities and other confounding factors like diet and ex-
ercise which have not been controlled.
There are some limitations in our study that should
also be considered. First, we studied a relatively small
sample of PHPT patients, however we intended to have
only patients whose diagnosis was confirmed by path-
ology and that had completed screening protocols. Sec-
ond, the cross-sectional design of the study prevents us
from comparing this group with a healthy control group.
However this study is the first to describe the prevalence
of MS in Mexican patients with PHPT, and the results
suggest that MS may be more prevalent in some groups
than previously expected. Populations where cardiovas-
cular risk factors are frequent could be adversely affected
if PHPT is also associated. Prospective studies of this
population including wider searches for metabolic, in-
flammatory and cardiovascular parameters are warranted
in order to properly assess their cardiovascular risk be-
fore and after surgery.
Conclusion
Our data shows the highest prevalence of MS in patients
with PHPT ever reported. In our population, this could be
related to the high prevalence of overweight and obesity.
The most prevalent components of MS in PHPT are
hypertriglyceridemia, central obesity and glucose metabol-
ism impairment. These prevalences are even higher than
reported in general population. We suggest that MS is in-
volved in the cardiovascular risk associated to PHPT.
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